# **Product** Data Sheet

## **HM03**

Target:

Cat. No.: HY-125974 CAS No.: 500565-15-1 Molecular Formula:  $C_{26}H_{27}CIN_4O_2$ Molecular Weight: 462.97

Pathway: Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Storage: Powder -20°C 3 years

HSP

4°C 2 years

-80°C In solvent 2 years

> -20°C 1 year

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 125 mg/mL (270.00 mM; Need ultrasonic)

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
|                              | 1 mM                          | 2.1600 mL | 10.7998 mL | 21.5997 mL |
|                              | 5 mM                          | 0.4320 mL | 2.1600 mL  | 4.3199 mL  |
|                              | 10 mM                         | 0.2160 mL | 1.0800 mL  | 2.1600 mL  |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 6.25 mg/mL (13.50 mM); Clear solution

#### **BIOLOGICAL ACTIVITY**

Description HM03 is a potent and selective HSPA5 (Heat shock 70kDa protein 5, also known as Bip, Grp78) inhibitor. HM03 has anticancer activity<sup>[1]</sup>. IC<sub>50</sub> & Target HSPA5

HM03 (0.1-50  $\mu$ M; 72 hours) exhibits over 50% inhibition at 25  $\mu$ M concentration in HCT116 cells<sup>[1]</sup>. ?HM03 forms more binding interactions with HSPA5 and HSPA9 than with the other HSP70 proteins  $\[1\]$ . ?HM03 exhibits promising inhibition activities from cancer cell viability and tumor inhibition assays<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay<sup>[1]</sup>

In Vitro

| Cell Line:       | HCT116 cells   |  |
|------------------|--|--|
| Concentration:   | 0.1, 1, 10, 25, 50 μΜ  |  |
| Incubation Time: | 72 hours   |  |
| Result:          | Exhibited prominent inhibition effect (18% survival at 25 μM). |  |

### **CUSTOMER VALIDATION**

• Proc Natl Acad Sci U S A. 2023 May 23;120(21):e2217119120.

See more customer validations on  $\underline{www.MedChemExpress.com}$ 

#### **REFERENCES**

[1]. Huang M, et al. Structure-based design of HSPA5 inhibitors: from peptide to small molecule inhibitors. Bioorg Med Chem Lett. 2013;23(10):3044-3050.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA